eShunt
Extending Minimally Invasive Surgery to Severe and Refractory Glaucoma Patients
Not available for sale
CorNeat eShunt
Implantation Animation
The CorNeat eShunt redefines glaucoma treatment for severe patients by effectively regulating intraocular pressure. It offers immediate and stable efficacy post-op, with pressure determined by its tube resistance to flow. The EverMatrix material covering the device's outlet prevents encapsulation and clogging. Positioned deep in the orbit, it benefits from positive pressure, reducing the risks of hypotony and avoiding blebs. The integral, non-degradable, tissue-integrating EverMatrix patch reduces tube exposure risk and cuts down implantation time to under 20 minutes. The eShunt's design guarantees reliable, long-lasting pressure regulation, providing new hope to patients suffering from this devastating, chronic, blinding disease.
Why eShunt ?
Longlasting
-
drainage site with minimal scarring potential
-
EverMatrix covered outlet minimizes encapsulation
Ease of Implantation
-
Implantation procedure can be completed in under 20 minutes
-
Integral EverMatrix™ patch relieves the need for suturing a tissue patch
Safe
-
Minimally invasive
-
No risk of hypotony due to positive pressure in drainage site
-
Nondegradbale patch - reduces risk of tube exposure
Cost-Effective
-
Saves significant OR time
-
reduces risk of complications requiring revision surgery
-
Improved economics for severe glaucoma treatment
Deterministic
-
stable pressure dictated by tube resistance and the pressure in the orbit
-
Adaptive flow mirrors pressure elevation
-
Effective immediately post-op
eShunt Innovation
Integral Patch
-
EverMatrix™ biologically integrates with surrounding tissue – shortening procedure time by 50%.
Inlet & Lumen
-
Tube resistance to flow imitates physiological outflow facility.
Outlet
-
Covered with EverMatrix and uniquely positioned in the intraconal space, deep in the orbit, so less likely to clog.
Positive pressure in the orbit reduces the risk of hypotony.